Pharmaceutical

RedHill and Hyloris sign agreement for Bekinda’s development

RedHill has signed an exclusive licensing agreement with Hyloris for the global development and commercialisation of RHB-102 (Bekinda).

Feb 27, 2025 - 06:00
RedHill and Hyloris sign agreement for Bekinda’s development
RedHill has signed an exclusive licensing agreement with Hyloris for the global development and commercialisation of RHB-102 (Bekinda).
Read the original article

Tags:

Previous Article

FDA approvals decline but drug innovation remains strong even among small sponsors

Next Article

Eli Lilly pays $10m upfront for Organovo’s FXR agonist

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Gilead and Merus enter trispecific antibody discovery deal

Gilead and Merus enter trispecific antibody discovery deal

Mar 7, 2024

After early-stage breast cancer, interrupting endocrine therapy to become pregnant didn’t raise risk of recurrence

After early-stage breast cancer, interrupting endocrine...

May 3, 2023

Reprieve for WuXi as Biosecure vote likely pushed to 2025

Reprieve for WuXi as Biosecure vote likely pushed to 2025

Dec 17, 2024